This concept is also supported by the DREAMseq trial demonstrating that patients with BRAF-mutated melanoma receiving first-line ICI and then targeted therapy had a better prognosis than those receiving initially targeted therapy and, subsequently, ICI. This evidence concerns the gene BRAF and melanoma.